Furthermore, the researchers noted a link between CDK4 expression and tumor clinicopathological characteristics: CDK4 expression significantly correlated with higher clinical stage and higher TNM grade in patients with synovial sarcoma, as well as with a worse clinical prognosis in patients with sarcoma [47]. The gene discussed is CDK4; the disease is synovial sarcoma.